Innovation Pharmaceuticals Inc. (IPIX)

Overview

Innovation Pharmaceuticals Inc. is a dynamic clinical stage biopharmaceutical company primarily focused on the development of innovative small molecule therapies. These cutting-edge treatments are aimed at addressing a wide range of conditions, including inflammatory diseases, various forms of cancer, dermatological issues, and anti-infective diseases. Originally operating under the name Cellceutix Corporation until June 2017, the company underwent a rebranding to better reflect its commitment to pioneering new treatments in the pharmaceutical field. Since its inception in 2005, Innovation Pharmaceuticals Inc. has been developing its portfolio from its headquarters located in Wakefield, Massachusetts. Through strategic collaborations and licensing agreements, such as those with Alfasigma S.p.A. and Fox Chase Chemical Diversity Center, Inc., Innovation Pharmaceuticals is advancing its research and expanding its impact in the healthcare sector.

Products and Services

• Brilacidin

As the flagship drug candidate of Innovation Pharmaceuticals Inc., Brilacidin exemplifies the company’s dedication to addressing a variety of medical challenges through innovative therapeutic approaches. Brilacidin is currently in development for multiple applications:

• Oral Mucositis: Innovation Pharmaceuticals is exploring Brilacidin’s potential to provide relief and treatment for oral mucositis, a common and debilitating side effect of cancer treatment that causes painful ulcers and sores in the mouth.
• Inflammatory Bowel Disease: Recognizing the need for new treatments in gastrointestinal disorders, Brilacidin is being studied for its potential to treat inflammatory bowel disease, offering hope to patients with conditions such as Crohn’s disease and ulcerative colitis.
• Acute Bacterial Skin and Skin Structure Infection (ABSSSI): Addressing the critical need for new antibiotics in the face of growing resistance, Brilacidin is under research as a novel treatment option for ABSSSI, aiming to provide an effective remedy for severe skin infections.
• COVID-19: In response to the global pandemic, Innovation Pharmaceuticals has also been evaluating Brilacidin’s utility as a potential treatment for COVID-19, highlighting the drug’s versatile therapeutic promise.